COVID-19 outcomes in MS: Observational study of early experience from NYU Multiple Sclerosis Comprehensive Care Center.

Objective: To report outcomes on patients with multiple sclerosis (MS) and related disorders with coronavirus disease 2019 (COVID-19) illness.

Methods: From March 16 to April 30, 2020, patients with MS or related disorders at NYU Langone MS Comprehensive Care Center were identified with laboratory-confirmed or suspected COVID-19. The diagnosis was established using a standardized questionnaire or by review of in-patient hospital records.

The Charlson comorbidity index is adapted to predict costs of chronic disease in primary care patients.

Objective: (1) To determine chronic illness costs for large cohort of primary care patients, (2) to develop prospective model predicting total costs over one year, using demographic and clinical information including widely used comorbidity index.

Study Design And Setting: Data including diagnostic, medication, and resource utilization were obtained for 5,861 patients from practice-based computer system over a 1-year period beginning December 1, 1993, for retrospective analysis. Hospital cost data were obtained from hospital cost accounting system.

Can disease management target patients most likely to generate high costs? The impact of comorbidity.

Context: Disease management programs are increasingly used to manage costs of patients with chronic disease.

Objective: We sought to examine the clinical characteristics and measure the health care expenditures of patients most likely to be targeted by disease management programs.

Design: Retrospective analysis of prospectively obtained data.